06826 HAOHAI BIOTEC
- 28.000
- -0.500-1.75%
HAOHAI BIOTEC News
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
On December 5, haohai biotec (06826) spent 0.8066 million Hong Kong dollars to repurchase 0.0295 million shares.
haohai biotec (06826) announced that the company invested 0.8066 million Hong Kong dollars on December 5, 2024...
Haohai Biotec (06826.HK) spent 0.199 million HKD to repurchase 7,200 shares on December 4.
On December 4, haohai biotec (06826.HK) announced that it spent 0.199 million Hong Kong dollars to repurchase 7200 shares on December 4.
haohai biotec (06826.HK) spent 0.363 million Hong Kong dollars to repurchase 0.013 million shares on December 3.
Grain Meeting December 3rd | haohai biotec (06826.HK) announced that on December 3, 2024, it spent 0.363 million Hong Kong dollars to repurchase 0.013 million shares at a repurchase price of HK$27.85-28 per share.
haohai biotec (06826.HK) has repurchased a total of 0.138 million shares of A-shares as of November 30, 2024.
Gelonghui, December 2nd丨haohai biotec (06826.HK) announced that as of November 30, 2024, the company has repurchased a total of 138,150 A-shares through centralized bidding trade, accounting for 0.06% of the company's total share capital of 234,190,295 shares. The highest fill price was 63.58 yuan per share, the lowest fill price was 62.73 yuan per share, and the total transaction amount was 8,725,748.33 yuan (excluding stamp duty, transaction commission, and other transaction costs).
Haohai Biotec (06826.HK) spent 0.2071 million Hong Kong dollars to repurchase 7500 shares on December 2nd.
On December 2, Gelonghui reported that haohai biotec (06826.HK) announced the repurchase of 7,500 shares at a cost of 0.2071 million Hong Kong dollars on December 2, 2024, with a repurchase price of 27.6-27.65 Hong Kong dollars per share.
Haohai Biotec (06826) plans to use no more than 0.4 billion yuan of temporarily idle raised funds for cash management.
Haohai Biotec (06826) announced that the company plans to use no more than 0.4 billion yuan (including this amount) of temporarily idle...
Shanghai Haohai Biological Technology (688366.SH): plans to use no more than 0.4 billion yuan of temporarily idle raised funds for cash management.
On November 29, Gelonghui reported that shanghai haohai biological technology (688366.SH) announced that the company plans to use temporarily idle raised funds for cash management, with a maximum amount not exceeding 400 million yuan, provided that it does not affect the normal progress of the company's fundraising investment plan. The funds will be used to purchase high-security, good liquidity, and guaranteed principal investment products (including but not limited to agreed deposits, notice deposits, term deposits, large certificates of deposit, income certificates, etc.), with a duration not exceeding the construction period of the fundraising projects and valid within 12 months from the date of approval by the board of directors. Within the aforementioned limit and timeframe, the company can recycle.
Shanghai Haohai Biological Technology (688366.SH): Shareholders Lou Guoliang collectively reduce their shareholding by no more than 0.8 million shares in the company.
On November 29, Gelonghui reported that Shanghai Haohai Biological Technology (688366.SH) announced that shareholder Mr. Lou Guoliang plans to reduce his shareholding by no more than 800,000 shares within three months starting from three trading days after this announcement, due to his own funding needs. This represents no more than 0.3416% of the company's total share capital of 234,190,295 shares, with the reduction of no more than 800,000 shares through centralized bidding and no more than 800,000 shares through block trading. The reduction price will be determined based on the secondary market price.
Haohai Biotec (06826) spent 0.5067 million Hong Kong dollars to repurchase 0.018 million shares on November 29.
haohai biotec (06826) announced that on November 29, 2024, the company invested 0.5067 million...
Haohai Biotec (06826) repurchased 0.01 million shares on November 28 for 0.2764 million HKD.
haohai biotec (06826) announced that on November 28, 2024, the company invested 27.64...
On November 27, haohai biotec (06826.HK) spent 0.292 million Hong Kong dollars to repurchase 0.0105 million shares.
On November 27, Gelonghui reported that haohai biotec (06826.HK) announced a repurchase of 0.0105 million shares at a cost of 0.292 million HKD on November 27, with a repurchase price of 27.65-28 HKD per share.
Haohai Biotec (06826.HK) spent 0.36 million HKD to repurchase 0.013 million shares on November 26.
Grain Meeting November 26th | Haohai Biotec (06826.HK) announced that on November 26th, it repurchased 0.013 million shares at a cost of 0.36 million Hong Kong dollars.
shanghai haohai biological technology (688366.SH): the company repurchased 0.0532 million shares of A shares for the first time.
On November 26, Ge Longhui reported that shanghai haohai biological technology (688366.SH) announced that on November 26, 2024, the company first repurchased 53,200 shares of its A-shares through the centralized bidding trading method on the shanghai exchange trading system, accounting for 0.02% of the company's total share capital of 234,190,295 shares, with a maximum fill price of 63.20 yuan/share, a minimum fill price of 62.81 yuan/share, and a total transaction amount of 3,355,310.81 RMB (excluding stamp duty, trading commissions, and other transaction costs).
haohai biotec (06826.HK) spent 0.3132 million Hong Kong dollars on November 21 to repurchase 0.011 million shares.
Grondlon November 21st | haohai biotec (06826.HK) announced that on November 21, 2024, it will spend 0.3132 million Hong Kong dollars to repurchase 0.011 million shares at a repurchase price of 28.4-28.55 Hong Kong dollars per share.
Huachuang Securities: The retail and social services sectors are experiencing a rebound in customer traffic, with both fundamentals and valuation recovering.
Looking ahead to 2025, the service consumer sector is experiencing a rapid turnaround and repair, with both the 'broad and profound' fundamentals and valuation repair taking effect, establishing a clear trend.
haohai biotec (06826.HK) spent 0.3102 million Hong Kong dollars on November 20 to repurchase 0.0108 million shares.
Gelonghui November 20th | haohai biotec (06826.HK) announced that on November 20, 2024, it spent 0.3102 million Hong Kong dollars to repurchase 0.0108 million shares at a repurchase price of 28.7-28.75 Hong Kong dollars per share.
Intelligent Hong Kong Stock Repurchase Statistics | November 20th
Hong Kong Stock Buyback Statistics | November 20th
On November 19, haohai biotec (06826.HK) spent 0.5506 million Hong Kong dollars to repurchase 0.0193 million shares.
Gelonghui, on November 19, announced that haohai biotec (06826.HK) spent 0.5506 million Hong Kong dollars to repurchase 0.0193 million shares on November 19, 2024, with a repurchase price of 28.4-28.6 Hong Kong dollars per share.
No Data
